NOLVADEX (tamoxifen citrate) is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, NOLVADEX (tamoxifen citrate) is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from NOLVADEX (tamoxifen citrate) therapy.
Think of Nolvadex as a regulator drug that helps control the amount of estrogen produced in the body so it won’t trigger long term negative side effects. Estrogen levels usually skyrocket after cycling with anabolic steroids and can cause gyno or abnormal swelling of the breasts in men as well as promote excess water retention which will definitely ruin the bodybuilding goals that you’ve spent hours and hours at the gym to achieve.
DOSAGE AND ADMINISTRATION
For patients with breast cancer, the recommended daily dose is 20-40 mg. Dosages greater than 20 mg per day should be given in divided doses (morning and evening).
In three single agent adjuvant studies in women, one 10 mg NOLVADEX (tamoxifen citrate) tablet was administered two (ECOG and NATO) or three (Toronto) times a day for two years. In the NSABP B-14 adjuvant study in women with node-negative breast cancer, one 10 mg NOLVADEX (tamoxifen citrate) tablet was given twice a day for at least 5 years. Results of the B-14 study suggest that continuation of therapy beyond five years does not provide additional benefit (see CLINICAL PHARMACOLOGY). In the EBCTCG 1995 overview, the reduction in recurrence and mortality was greater in those studies that used tamoxifen for about 5 years than in those that used tamoxifen for a shorter period of therapy. There was no indication that doses greater than 20 mg per day were more effective. Current data from clinical trials support 5 years of adjuvant NOLVADEX (tamoxifen citrate) therapy for patients with breast cancer.
Ductal Carcinoma in Situ (DCIS)
The recommended dose is NOLVADEX (tamoxifen citrate) 20 mg daily for 5 years.
Reduction in Breast Cancer Incidence in High Risk Women
The recommended dose is NOLVADEX (tamoxifen citrate) 20 mg daily for 5 years. There are no data to support the use of NOLVADEX (tamoxifen citrate) other than for 5 years (See CLINICAL PHARMACOLOGY-Clinical Studies – Reduction in Breast Cancer Incidence in High Risk Women).